Loading...
XETRDMP
Market cap2.12bUSD
Dec 23, Last price  
37.80EUR
1D
-0.53%
1Q
12.84%
IPO
40.42%
Name

Dermapharm Holding SE

Chart & Performance

D1W1MN
XETR:DMP chart
P/E
32.63
P/S
1.79
EPS
1.16
Div Yield, %
2.78%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
14.68%
Revenues
1.14b
+10.79%
391,340,000384,843,000444,478,000467,117,000572,424,000700,879,000793,829,000942,912,0001,024,776,0001,135,351,000
Net income
62m
-53.54%
-61,00012,701,00016,824,00077,744,00075,323,00077,196,00085,826,000209,583,000134,236,00062,368,000
CFO
219m
-23.95%
54,256,00040,377,00076,778,00086,736,000159,128,000100,614,000131,098,000250,368,000288,533,000219,422,000
Dividend
Jun 28, 20240.88 EUR/sh
Earnings
Mar 26, 2025

Profile

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
IPO date
Feb 09, 2018
Employees
3,404
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,135,351
10.79%
1,024,776
8.68%
942,912
18.78%
Cost of revenue
522,102
443,869
402,274
Unusual Expense (Income)
NOPBT
613,249
580,907
540,638
NOPBT Margin
54.01%
56.69%
57.34%
Operating Taxes
45,462
83,680
84,073
Tax Rate
7.41%
14.41%
15.55%
NOPAT
567,787
497,227
456,565
Net income
62,368
-53.54%
134,236
-35.95%
209,583
144.20%
Dividends
(56,532)
(116,833)
(47,379)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
116,430
4,887
5,580
Long-term debt
982,207
524,295
586,935
Deferred revenue
9,204
9,456
Other long-term liabilities
268,325
91,269
131,289
Net debt
864,568
302,410
326,307
Cash flow
Cash from operating activities
219,422
288,533
250,368
CAPEX
(41,541)
(39,014)
(61,203)
Cash from investing activities
(415,432)
(99,008)
(129,347)
Cash from financing activities
204,538
(199,768)
(80,979)
FCF
347,661
531,285
408,333
Balance
Cash
159,542
161,358
172,061
Long term investments
74,527
65,414
94,147
Excess cash
177,301
175,533
219,062
Stockholders' equity
444,258
431,702
399,044
Invested Capital
1,705,313
863,131
941,624
ROIC
44.21%
55.10%
48.76%
ROCE
32.57%
53.33%
45.18%
EV
Common stock shares outstanding
53,840
53,840
53,840
Price
Market cap
EV
EBITDA
717,836
675,816
595,797
EV/EBITDA
Interest
54,968
12,338
8,837
Interest/NOPBT
8.96%
2.12%
1.63%